Guidelines for Radiotherapy of Esophageal Carcinoma (2020 Edition)

Abstract

Esophageal carcinoma in China differs greatly from that in European and American countries in terms of etiology, pathological type, high-incidence site, etc. [...]the European and American guidelines on radiotherapy for esophageal carcinoma cannot be applied in clinical practice in China. SUPPLEMENTARY EXAMINATION Laboratory examination General examination including blood routine, liver function and kidney function, viral serology, electrolyte, blood glucose, coagulation function, urine routine, fecal routine, etc. Detection of immune-related markers Immunotherapy is used as the second-line and above treatment for advanced esophageal carcinoma and first-line combined chemotherapy or postoperative adjuvant therapy; eligible patients should be tested for programmed death protein ligand 1 (PD-L1) and its combined positive score (CPS), tumor mutation coincidence (TMB), microsatellite instability (MSI), and mismatch repair protein loss (dMMR). According to its degree of differentiation, SCC is divided into well-differentiated, moderately differentiated, and poorly differentiated forms.